Braun Stacey Associates Inc. Sells 1,732 Shares of Eli Lilly and Company (NYSE:LLY)

Braun Stacey Associates Inc. lessened its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.3% in the first quarter, according to its most recent filing with the SEC. The fund owned 50,323 shares of the company's stock after selling 1,732 shares during the period. Eli Lilly and Company comprises about 1.7% of Braun Stacey Associates Inc.'s portfolio, making the stock its 12th largest holding. Braun Stacey Associates Inc.'s holdings in Eli Lilly and Company were worth $41,562,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. WestEnd Advisors LLC raised its holdings in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares during the period. Citizens National Bank Trust Department increased its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares in the last quarter. Mascagni Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $43,000. O Brien Wealth Partners LLC lifted its position in shares of Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after acquiring an additional 12 shares in the last quarter. Finally, Prudent Man Investment Management Inc. acquired a new position in Eli Lilly and Company in the 4th quarter worth approximately $48,000. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

LLY has been the topic of several recent analyst reports. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Wall Street Zen downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Saturday, June 28th. Guggenheim reaffirmed a "buy" rating and set a $936.00 target price on shares of Eli Lilly and Company in a research note on Friday, June 20th. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Finally, Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $1,011.61.

Eli Lilly and Company Stock Up 0.0%

Shares of LLY traded up $0.32 during mid-day trading on Friday, hitting $779.60. 1,450,772 shares of the company's stock were exchanged, compared to its average volume of 3,667,986. The stock has a market cap of $738.85 billion, a price-to-earnings ratio of 63.43, a P/E/G ratio of 1.14 and a beta of 0.40. The firm has a fifty day moving average of $773.61 and a two-hundred day moving average of $799.96. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same period in the previous year, the company earned $2.58 earnings per share. The company's quarterly revenue was up 45.2% compared to the same quarter last year. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.